相似文献
1
Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
Trends Microbiol. 2019 Jan;27(1):8-16. doi: 10.1016/j.tim.2018.08.008. Epub 2018 Sep 7.
2
Ebola: Lessons on Vaccine Development.
Annu Rev Microbiol. 2018 Sep 8;72:423-446. doi: 10.1146/annurev-micro-090817-062414.
3
Ebola virus vaccines: an overview of current approaches.
Expert Rev Vaccines. 2014 Apr;13(4):521-31. doi: 10.1586/14760584.2014.885841. Epub 2014 Feb 27.
4
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
5
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
Science. 2015 Aug 14;349(6249):739-42. doi: 10.1126/science.aab3920. Epub 2015 Aug 6.
6
The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
Hum Vaccin Immunother. 2018;14(9):2107-2113. doi: 10.1080/21645515.2018.1473698. Epub 2018 Jun 18.
7
Correlates of vaccine-induced protective immunity against Ebola virus disease.
Semin Immunol. 2018 Oct;39:65-72. doi: 10.1016/j.smim.2018.07.003. Epub 2018 Jul 21.
8
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
9
Ebola virus vaccines - reality or fiction?
Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. doi: 10.1080/14760584.2016.1178068. Epub 2016 May 9.
10
Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.
Lancet Infect Dis. 2015 Mar;15(3):356-9. doi: 10.1016/S1473-3099(14)71071-0. Epub 2015 Jan 14.
引用本文的文献
1
Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.
bioRxiv. 2025 Mar 2:2025.03.02.641072. doi: 10.1101/2025.03.02.641072.
2
Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.
Vaccines (Basel). 2023 Dec 25;12(1):24. doi: 10.3390/vaccines12010024.
3
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
J Infect Dis. 2024 Apr 12;229(4):1068-1076. doi: 10.1093/infdis/jiad350.
4
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.
NPJ Vaccines. 2023 Jul 11;8(1):99. doi: 10.1038/s41541-023-00699-7.
5
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection.
Front Immunol. 2023 Apr 17;14:1156758. doi: 10.3389/fimmu.2023.1156758. eCollection 2023.
6
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Cell Rep. 2023 Apr 25;42(4):112402. doi: 10.1016/j.celrep.2023.112402. Epub 2023 Apr 15.
7
Bridging Animal and Human Data in Pursuit of Vaccine Licensure.
Vaccines (Basel). 2022 Aug 25;10(9):1384. doi: 10.3390/vaccines10091384.
8
Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates.
Vaccines (Basel). 2022 Aug 18;10(8):1338. doi: 10.3390/vaccines10081338.
9
A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease.
Vaccines (Basel). 2022 Jun 23;10(7):1004. doi: 10.3390/vaccines10071004.
10
Tracking ebolavirus genomic drift with a resequencing microarray.
PLoS One. 2022 Feb 10;17(2):e0263732. doi: 10.1371/journal.pone.0263732. eCollection 2022.
本文引用的文献
1
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.
2
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.
3
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.
Cell Rep. 2017 Aug 29;20(9):2251-2261. doi: 10.1016/j.celrep.2017.08.023.
4
Vaccines against Ebola virus.
Vaccine. 2018 Aug 28;36(36):5454-5459. doi: 10.1016/j.vaccine.2017.07.054. Epub 2017 Aug 2.
5
Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.
J Virol. 2017 Aug 10;91(17). doi: 10.1128/JVI.00479-17. Print 2017 Sep 1.
6
Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
J Virol. 2017 Jul 27;91(16). doi: 10.1128/JVI.00652-17. Print 2017 Aug 15.
7
T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.
Emerg Microbes Infect. 2017 Jun 7;6(6):e46. doi: 10.1038/emi.2017.31.
8
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.
9
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
EBioMedicine. 2017 May;19:107-118. doi: 10.1016/j.ebiom.2017.03.045. Epub 2017 Apr 5.
10
Transcriptomic analysis reveals a previously unknown role for CD8 T-cells in rVSV-EBOV mediated protection.
Sci Rep. 2017 Apr 20;7(1):919. doi: 10.1038/s41598-017-01032-8.
Zotero 插件